在B-ALL患者的免疫疗法药物反应的差异,包括blinatumomab和 inotuzumab ozogamicin
Zhi-Yin Liu1, Ze-Ying Yan1, Jian-Feng Li2
1Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Road II 197, Shanghai, China.
International journal of hematology
|April 15, 2025
概括
免疫疗法,包括blinatumomab和 inotuzumab ozogamicin,在不同的B细胞前体急性淋巴细胞白血病 (B-ALL) 患者群体中显示出特定的优势. 遗传特征,如新型融合基因,可能会影响治疗反应和预后.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- B细胞前体急性淋巴细胞白血病 (B-ALL) 治疗正在通过免疫疗法发展.
- 布利纳图莫马布 (Blina) 和伊诺图祖马布 (inotuzumab ozogamicin) (InO) 是主要的免疫疗法.
- 了解基于遗传因素的治疗反应至关重要.
研究的目的:
- 为了追溯分析布利纳图马布和伊诺图祖马布在B-ALL患者中的效果.
- 研究新型融合基因对免疫治疗反应的影响.
- 确定对特定免疫疗法有差异性反应的患者子组.
主要方法:
- 对21名B-ALL患者 (18名新诊断,3名复发) 的回顾性研究.
- RNA测序用于识别新型基因融合.
- 基于遗传特征的blinatumomab 和 inotuzumab ozogamicin 治疗反应的分析.
主要成果:
- 发现了五种新的基因融合:ADD1::JAK2,PVT1::IGLL5,PAX5::KANK2,ETV6::BCL2L14和CDKN2A::TGFBR3.
- 患有PAX5::KANK2和CREBBP::ZNF384融合的患者表现出对blinatumomab的最佳反应.
- 患有CDKN2A::TGFBR3或BCR::ABL阳性的患者对blinatumomab的反应较差.
- 一个子组在最初对布利纳图马布无反应后,对伊诺图祖马布臭胺素有反应.
- PVT1::IGLL5融合与最差的预后有关.
结论:
- 布利纳图莫马布和伊诺图祖马布 (inotuzumab ozogamicin) 在特定的B-ALL患者群体中显示出明显的治疗优势.
- 内在的遗传特征,包括新的融合基因,可能会影响免疫治疗的疗效.
- 基于基因分析的个性化免疫疗法策略可能会改善B-ALL治疗结果.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.7K
相关概念视频
01:27Tumor Immunotherapy
404
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
404
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K